The receptor tyrosine kinase ROR1 has been shown to play a role in therapeutical efficiency in treatments for CLL and multiple solid tumors and immunotherapy targeting ROR1 has showed significant improvements in preclinical and clinical studies [23]. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.